Medicine and Dentistry
Cell-Free DNA
84%
Neoplasm
83%
Metastatic Breast Cancer
79%
Methylation
66%
Aneuploidy
65%
Circulating Tumor Cell
59%
Circulating Tumor DNA
57%
Liquid Biopsy
49%
Systematic Review
39%
Breast Cancer
33%
DNA Methylation
29%
Wart Virus
28%
Biological Marker
28%
Colorectal Cancer
28%
Screening Test
26%
Rectum Cancer
26%
Estrogen Receptor
26%
Diseases
24%
DNA Sequence
22%
Copy Number Variation
21%
5 Acetamido 2 (2 Methoxyethoxy)acetophenone
19%
Metastatic Carcinoma
18%
Triage
18%
Biopsy
18%
Disease Exacerbation
17%
Whole Genome Sequencing
16%
Liver Metastasis
15%
Colposcopy
14%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
14%
Cell Count
14%
Malignant Neoplasm
13%
Cervical Cancer
13%
microRNA
13%
Cancer Cell
13%
Cerebrospinal Fluid
13%
Urothelial Cancer
13%
Adenoma
13%
Lymph Node
13%
Adverse Event
13%
Gene Expression Profiling
13%
Radiation Therapy
13%
Chemoradiation Therapy
13%
Colon Cancer
13%
Meta-Analysis
13%
Vulva
13%
Formaldehyde
13%
Prostate Cancer
13%
Pembrolizumab
13%
Trastuzumab
13%
microRNA 124
13%
Biochemistry, Genetics and Molecular Biology
Methylation
97%
Circulating Tumor DNA
71%
Aneuploidy
65%
DNA Methylation
43%
Wart Virus
41%
Whole Genome Sequencing
39%
Screening Test
35%
DNA Sequence
33%
Estrogen Receptor
26%
Cancer Cell
24%
Next Generation Sequencing
21%
Progression Free Survival
19%
Mitogen-Activated Protein Kinase
17%
RNA Sequence
17%
Differentially Methylated Regions
15%
Transcriptomics
15%
Epigenetics
14%
Germline
13%
Dynamics
13%
Single-Nucleotide Polymorphism
13%
MicroRNA
13%
Microsatellite DNA
13%
Pharmacokinetics
13%
Germ Cell
13%
Pembrolizumab
13%
Promoter Region
13%
Pharmacodynamics
13%
Anchorage Independent Growth
13%
Quality Adjusted Life Year
13%
P53
13%
Gene Expression Profiling
13%
Cell Adhesion Molecule 1
13%
Gene Amplification
13%
Poly ADP Ribose Polymerase
13%
Leukapheresis
13%
Transcription
13%
Copy-Number Variation
11%
DNA Analysis
11%
Cyclin-Dependent Kinase 4
11%
Chromosomal Aberration
10%
Screening
10%
Polymerase Chain Reaction
10%
Cell Count
8%
Cancer Screening
8%
Overall Survival
8%
Gene Mutation
8%
Tumor Volume
7%
Spike
6%
Origin of Replication
6%
FBXW7
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Metastatic Breast Cancer
66%
Circulating Tumor DNA
60%
Aneuploidy
49%
Biological Marker
48%
Breast Cancer
46%
Abemaciclib
26%
Estrogen Receptor
26%
Chemotherapy
22%
Malignant Neoplasm
20%
Palbociclib
13%
Kidney Metastasis
13%
Ribociclib
13%
Receptor
13%
Phase II Trials
13%
Renal Cell Carcinoma
13%
Protein P53
13%
Trastuzumab
13%
Taxane
13%
Colorectal Liver Metastasis
13%
Rectum Cancer
13%
Liver Cell Carcinoma
13%
Prostate Cancer
13%
Liver Cirrhosis
13%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
13%
Metastatic Melanoma
13%
Ovary Cancer
13%
Disease Exacerbation
13%
Pembrolizumab
13%
Disease
9%
Pharmacodynamics
8%
Prematurity
8%
Ovary Carcinoma
8%
Cyclin Dependent Kinase 4
8%
Recurrence Free Survival
8%
Overall Survival
7%
Minimal Residual Disease
7%
Recurrent Disease
7%
Progression Free Survival
7%
Carcinogenesis
6%
RNA-Sequencing
6%
Mitogen Activated Protein Kinase
6%
Endocrine Therapy
5%